Standard of Care Versus Urine Testing With Selective PHarmacogenomics for Effective Drug and Dosing REgimens

PHASE4UnknownINTERVENTIONAL
Enrollment

14,000

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

December 31, 2018

Conditions
Target Drug-related Adverse Events
Interventions
OTHER

Urine diagnostic testing as SOC, drug regimen changes per SOC

OTHER

Urine diagnostic testing with selective PGx testing, drug regimen changes based on PGx test results

Trial Locations (1)

37879

RECRUITING

Donald H. Deaton, Jr., DO, Tazewell

Sponsors
All Listed Sponsors
collaborator

Syntactx

NETWORK

lead

InSource Diagnostics

INDUSTRY